Accelerating Cell & Gene Therapies Through Innovative In Vivo & Ex Vivo Platforms, Targeted Delivery & Cost-Effective Manufacturing Towards Regulatory Harmonization in Oncology, Autoimmune & Beyond
South Korea is rapidly advancing its cell and gene therapy (CGT) ecosystem, with key milestones such as Curocell’s Rimqarto becoming the first MFDS-approved cell therapy, and continued innovation from companies like Vaxcellbio and Rznomics advancing next-generation modalities. More recently, breakthroughs in in vivo CAR therapies, enhanced LNP and AAV delivery platforms, and advanced manufacturing have accelerated development timelines in the clinic.
The inaugural World Cell & Gene Therapy Summit South Korea unites international and local industry experts to share insights into better understanding of cellular microenvironments and gene editing tools. From T-Cells, NK cells, macrophages and stem cells, the agenda will explore how different cell types are being harnessed to combat oncology, autoimmune diseases and beyond.
As part of the World Advanced Therapeutics Summit by Hanson Wade, this event offers a platform to connect with leaders across cell, gene and RNA therapies working to establish South Korea as a global hub for advanced biopharma innovation.
Sharing our findings and perspectives in the field of RNA therapeutics is not about competing, but about complementing one another. This gathering will be an ideal platform to drive technological progress and reach a consensus on the future of RNA-based medical treatments.
Seungryul Han, Head of R&D (Director), Rznomics
This meeting will provide a valuable opportunity to share practical insights from successful and advanced CG&T leaders in Korea, while also learning from global leaders across the CG&T field.
Gene Lee Meyers, Business Development Lead, Curocell
The summit is a premier global forum to exchange insights across Asia, the US and the EU, fostering the cross-regional collaborations essential to accelerating clinical innovation. It is an invaluable opportunity to shape the future of cell and gene therapy alongside the global scientific, biotech and Pharma communities.
Peggy Sotiropoulou, Chief Scientific Officer, TKnife Therapeutics
Delivery is the rate-limiting step in modern cell and gene therapy. This summit gathers the right people to address it, and I am glad to contribute the perspective of a platform built around engineered natural nanoparticles.
Gi-Hoon Nam, Chief Executive Officer, Shiftbio
Cell and gene therapy is delivering results today. Our clinical data with NK cell therapy and next-generation CAR platforms show that durable responses in refractory cancers are achievable. Conferences like this are where the collaborations that turn these innovations into standard-of-care therapies are born.
Je-Jung Lee, Chief Executive Officer, VaxCell Bio
This meeting provides a unique platform to bridge cutting-edge scientific innovation with translational and clinical development in the rapidly evolving cell and gene therapy field. I believe it is particularly valuable for fostering collaboration across academia and industry to accelerate the development of next-generation immune cell therapies, including CAR-NK approaches, for both cancer and non-oncology indications.
Mihue Jang, Principal Research Scientist, Korea Institute of Science & Technology
Explore the Full Event Guide
- Discover, produce, and accelerate CGT to reduce time to patient care
- Gain insights from 18+ Korean-based and international speakers
- Dive into 20+ data driven case-studies from pre-clinical research to GMP commercial
- Engage in unrivalled networking opportunities from experts across cell, gene and RNA therapy fields
Speakers
Attending Companies Include
Explore the Agenda
Hear the latest technology innovations taking place within South Korea and gain exclusive insights on the progress in development globally.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean Advanced Therapeutics leaders.
Join Biopharma Experts
Be part of the hottest conversations with like-minded scientists, C-level executives, heads, managers, VPs, and more across discovery, clinical and CMC functions.